Dr. Reddy’s Laboratories’ subsidiary Promius Pharma has reported positive results from the clinical trial of its ZEMBRACE SymTouch (sumatriptan injection) to treat acute migraine headache.

EMBRACE SymTouch is a prescription medicine indicated for the treatment of acute headaches with or without aura.

With 268 subjects, the multi-centre, placebo-controlled trial saw 3mg ZEMBRACE SymTouch meet both its primary and various secondary endpoints.

The investigational candidate reduced migraine pain in a high proportion of subjects at two hours after dosing.

“Physicians can consider this low-dose 3mg injectable sumatriptan as an effective treatment option for their migraine patients.”

During the trial, ZEMBRACE SymTouch was found to be well-tolerated, with 33.3% of the participants experiencing treatment-emergent adverse events (TEAE) compared to 13.4% with placebo.

Triptan-related TEAEs were observed in 7.2% of patients within two hours post-dose and the results indicated no treatment-emergent serious adverse events (SAE).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Study author and Baptist Medical Group headache clinic director Stephen Landy said: “This multi-centre, randomised, double-blind, placebo-controlled trial demonstrates that the 3mg dose of sumatriptan in ZEMBRACE SymTouch provided rapid, complete pain relief in a significant proportion of patients with a low rate of side effects and no SAEs.

“Physicians can consider this low-dose 3mg injectable sumatriptan as an effective treatment option for their migraine patients.”